Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sramek

Showing results (41-50 of 156) with videos related to

Pageof 16
Sort By:
Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration|December 1, 1996
The bridging concept: optimizing dose for phase II/III in Alzheimer's diseaseN R Cutler, J J Sramek, J R Kilborn
Drugs|May 1, 1982
Management of tardive dyskinesia: current updateG M Simpson, E H Pi, J J Sramek
The Annals of Pharmacotherapy|October 31, 2000
Mild cognitive impairment: emerging therapeuticsJ J Sramek, A E Veroff, N R Cutler
Drugs|February 1, 1981
Adverse effects of antipsychotic agentsG M Simpson, E H Pi, J J Sramek
Journal of Clinical Psychopharmacology|August 1, 1986
Hepatic reaction to carbamazepineJ F Costa, J J Sramek, J M Herrera
Archives of Biochemistry and Biophysics|June 1, 1977
Sulfhydryl group reactivity in the Escherichia coli CoA transferaseS J Sramek, F E Frerman, M B Adams
The American Journal of Psychiatry|July 1, 1988
Exacerbation of psychosis after discontinuation of carbamazepine treatmentC W Heh, J Sramek, J Herrera, et al.
Hospital & Community Psychiatry|April 1, 1986
An update on tardive dyskinesiaG M Simpson, E H Pi, J J Sramek
Clinical Therapeutics|May 1, 1997
Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxietyJ J Sramek, E J Frackiewicz, N R Cutler
The Annals of Pharmacotherapy|May 20, 1999
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer diseaseW J Krall, J J Sramek, N R Cutler
Pageof 16

Showing results (41-50 of 156) with videos related to

Sort By:
Pageof 16
Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration|December 1, 1996
The bridging concept: optimizing dose for phase II/III in Alzheimer's diseaseN R Cutler, J J Sramek, J R Kilborn
Drugs|May 1, 1982
Management of tardive dyskinesia: current updateG M Simpson, E H Pi, J J Sramek
The Annals of Pharmacotherapy|October 31, 2000
Mild cognitive impairment: emerging therapeuticsJ J Sramek, A E Veroff, N R Cutler
Drugs|February 1, 1981
Adverse effects of antipsychotic agentsG M Simpson, E H Pi, J J Sramek
Journal of Clinical Psychopharmacology|August 1, 1986
Hepatic reaction to carbamazepineJ F Costa, J J Sramek, J M Herrera
Archives of Biochemistry and Biophysics|June 1, 1977
Sulfhydryl group reactivity in the Escherichia coli CoA transferaseS J Sramek, F E Frerman, M B Adams
The American Journal of Psychiatry|July 1, 1988
Exacerbation of psychosis after discontinuation of carbamazepine treatmentC W Heh, J Sramek, J Herrera, et al.
Hospital & Community Psychiatry|April 1, 1986
An update on tardive dyskinesiaG M Simpson, E H Pi, J J Sramek
Clinical Therapeutics|May 1, 1997
Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxietyJ J Sramek, E J Frackiewicz, N R Cutler
The Annals of Pharmacotherapy|May 20, 1999
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer diseaseW J Krall, J J Sramek, N R Cutler
Pageof 16